2024 Asia Conference on Lung Cancer (ACLC) - Poster & ePosters-PP02.42

PP02.42 - Xiru Quan

Pdf Summary

This study from Shanghai Chest Hospital, conducted by Xiru Quan and Shun Lu, investigates the impact of different TP53 mutation subtypes on the effectiveness of first-line immunotherapy in patients with locally advanced or metastatic lung adenocarcinoma (LUAD), a subtype of non-small cell lung cancer (NSCLC). Immunotherapy, particularly immune checkpoint inhibitors, is a primary treatment for NSCLC without targetable genetic alterations.<br /><br />A retrospective cohort of patients from January 2018 to November 2022 was analyzed. The study included 129 patients with stage IIIB-IV LUAD and confirmed TP53 mutations, identified through next-generation sequencing (NGS). The participants received immunotherapy, either as monotherapy or in conjunction with chemotherapy.<br /><br />The researchers specifically examined the frameshift mutation in the TP53 gene, which is prevalent in LUAD and known for its tumor suppressor properties. Preliminary findings indicate that TP53 frameshift mutations might serve as a negative biomarker for predicting the efficacy of first-line immunotherapy in LUAD patients. This conclusion implies that patients with TP53 frameshift mutations may have reduced benefit from such treatments compared to those with other TP53 mutations.<br /><br />Survival outcomes, namely progression-free survival (PFS) and overall survival (OS), were the primary endpoints of the study. Figures illustrating Kaplan–Meier survival analyses for these outcomes were provided, comparing patients with TP53 frameshift mutations to those without. The study also described the exclusion criteria and sequencing methods used to identify mutations, ensuring a focus on patients for whom immunotherapy efficacy could be accurately assessed.<br /><br />This research emphasizes the potential role of genetic profiling in personalizing treatment strategies for lung cancer, highlighting the need for further investigation into TP53 mutation subtypes as potential biomarkers for selecting appropriate therapies.

Keywords

TP53 mutation

lung adenocarcinoma

immunotherapy

non-small cell lung cancer

frameshift mutation

biomarker

next-generation sequencing

progression-free survival

overall survival

genetic profiling